Introduction Serum amyloid A (SAA) is a sensitive inflammatory marker rapidly increased during the acute phase, followed by a steady decline to physiological levels during resolution. While resolution and SAA reduction have been documented, the exact mechanism remains elusive. Although antibodies against SAA (anti-SAA) have been previously identified in healthy blood donors (HBDs) in smaller, preliminary studies, their potential function is still unclear.
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Objectives To detect anti-SAA and anti-SAA1a in the sera of 300 HBDs using ELISA, characterise their subclasses and avidity. Additionally, we aimed to evaluate their presence in intravenous immunoglobulin (IVIG) and potential effects on released IL-6 from SAA-treated peripheral blood mononuclear cells (PBMCs). Methods An in-house ELISA was adapted from Rosenau and Schur 1 and developed 2 for detection of anti-SAA and antiSAA1a. Both antibody fractions were isolated from IVIG using MicroLink Protein Coupling Kit (Thermo Scientific). PBMCs were purified from 5 HBDs by density gradient centrifugation and stimulated with SAA or SAA1a (1.5 mg/ml) in the presence/absence of anti-SAA and anti-SAA1a for 5 hours, 37°C. IL-6 concentration was measured in supernatants by ELISA (Invitrogen). Results The median (IQR) absorbance in HBDs was 0.655 (0.262-1.293) for anti-SAA and 0.493 (0.284-0.713) for antiSAA1a. Both anti-SAA and anti-SAA1a reached peak levels between 41-50 years and diminished with age, with women exhibiting significantly higher levels than men. Good positive correlation was observed between anti-SAA and anti-SAA1a. Both antibodies were prevalently of the IgG subclass, with heterogeneous to high avidity and were detected also in IVIG. Stimulation of PBMCs with SAA significantly induced IL-6 release (mean ±SD) (389.5±184.4 pg/ml) with levels decreasing significantly upon addition of 4.5 (131.4±44.4 pg/ml) or 9.0 mg/ml (118.1±57.4 pg/ml) anti-SAA. A similar trend was also found for SAA1a and anti-SAA1a. Conclusions Anti-SAA could play a physiological role in downregulating proinflammatory activity of SAA and could represent an attractive, novel therapeutic option for patients with chronic inflammatory diseases.
Introduction Fibroblast-like synoviocytes (FLS) are increasingly recognised as major pathogenic cells in synovial inflammation of patients with Rheumatoid Arthritis (RA). In response to pro-inflammatory stimuli, such as TNF, FLS produce vast amounts of cytokines and chemokines that help to recruit and activate immune cells and drive the local inflammatory process. The pathways and transcription factors that determine the inflammatory response in FLS are, however, largely unexplored. Objectives To investigated the potential contribution of the transcription-factor IRF1 to the inflammatory gene expression in FLS. Methods Expression of IRF1 in synovial tissue samples (12 RA and 8 osteoarthritis (OA) patients) was assessed by immunohistochemistry (IHC). Moreover, FLS were isolated according to established protocols and cultured using 2-D or 3-D culture techniques. IRF1expression in response to TNF was determined by western blots, qPCR, immunofluorescence microscopy or IHC. FLS were also stimulated with TNF in the presence or absence of IRF1 siRNA pools. Expression of pro-inflammatory cytokines and chemokines was measured by qPCR. Results IRF1 expression was significantly increased in rheumatoid synovial tissues as compared to patients with OA on protein level. RA-FLS stimulation with TNF ex vivo caused rapid upregulation of IRF1 and proved the involvement of TNF in the regulation of IRF1. Immunofluorescence analysis further revealed that IRF1 was mainly localised in the nucleus of TNF-stimulated FLS. Moreover, also chronic TNF exposure of FLS grown in a 3-D synovial tissue culture system promoted the expression of IRF1. siRNA-mediated knockdown of IRF1 in FLS significantly reduced the TNF-induced expression of pro-inflammatory cytokines and chemokines, such as IL6, CCL7, CXCL11 and TNFSF13B, which confirmed the role of IRF1 as a critical regulator of proinflammatory genes in RA FLS. Conclusions Our data reveal that IRF1 is crucial for the inflammatory response of FLS and support the idea that IRF1 might be an exciting therapeutic target in patients with RA. Disclosure of interest None declared
